Pharmacology

1. Introduction/Overview Myasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by fluctuating, fatigable weakness of skeletal muscles. The condition results from an antibody-mediated attack on postsynaptic nicotinic acetylcholine receptors at the neuromuscular junction, impairing synaptic transmission and leading to muscle weakness. The pharmacological management of myasthenia gravis represents a cornerstone of treatment, aimed at … Read more

Introduction/Overview Glaucoma represents a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and associated visual field loss. Elevated intraocular pressure remains the primary modifiable risk factor, though normal-tension glaucoma is also recognized. The pharmacological management of glaucoma is fundamentally directed toward reducing intraocular pressure, thereby slowing disease progression and preserving visual … Read more

1. Introduction/Overview Glaucoma represents a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and corresponding visual field loss. Elevated intraocular pressure remains the primary modifiable risk factor, though normal-tension glaucoma confirms that other factors contribute to pathogenesis. The pharmacological management of glaucoma is fundamentally directed toward reducing intraocular pressure, thereby slowing … Read more

Introduction/Overview Ganglionic blockers constitute a class of pharmacological agents that inhibit neurotransmission within autonomic ganglia. These drugs act as antagonists at nicotinic acetylcholine receptors (nAChRs) located on postganglionic neurons in both sympathetic and parasympathetic ganglia. By impeding the action of acetylcholine released from preganglionic neurons, these agents produce a broad and non-selective blockade of the … Read more

Introduction/Overview Beta-adrenergic blockers, commonly termed beta-blockers, represent a cornerstone class of therapeutic agents in cardiovascular medicine and beyond. These drugs function as competitive antagonists at beta-adrenergic receptors, thereby modulating the sympathetic nervous system’s influence on various organ systems. The clinical introduction of propranolol in the 1960s marked a paradigm shift in the management of angina … Read more

Introduction/Overview Alpha adrenergic blocking agents, commonly termed alpha blockers, constitute a fundamental class of drugs that antagonize the physiological effects mediated by catecholamines at alpha adrenergic receptors. These receptors are integral components of the sympathetic nervous system, regulating vascular tone, smooth muscle contraction, and a spectrum of metabolic processes. The therapeutic modulation of these receptors … Read more

Introduction/Overview Alpha adrenergic blockers, also known as alpha antagonists, constitute a fundamental class of drugs that inhibit the action of catecholamines at alpha adrenergic receptors. These receptors are integral components of the sympathetic nervous system, mediating a wide array of physiological responses including vascular tone, smooth muscle contraction, and metabolic processes. The therapeutic modulation of … Read more

Introduction/Overview Sympathomimetic agents constitute a fundamental class of drugs that mimic or enhance the actions of endogenous catecholamines, primarily norepinephrine and epinephrine, at adrenergic receptors. These agents are integral to the management of numerous acute and chronic medical conditions, ranging from cardiovascular emergencies to respiratory diseases. The clinical relevance of sympathomimetics is underscored by their … Read more

Introduction/Overview Anticholinergic agents, also referred to as muscarinic receptor antagonists or parasympatholytics, constitute a fundamental class of drugs in clinical medicine. These compounds exert their primary therapeutic and adverse effects by competitively inhibiting the action of acetylcholine at muscarinic cholinergic receptors within the autonomic nervous system and central nervous system. The clinical relevance of these … Read more

Introduction/Overview Parasympathomimetics, also termed cholinomimetics, constitute a class of pharmacological agents that mimic or potentiate the actions of the endogenous neurotransmitter acetylcholine (ACh) at effector organs of the parasympathetic nervous system. These drugs produce effects collectively known as “muscarinic” or “cholinergic” effects, which are characterized by the conservation of bodily energy, promotion of digestion, and … Read more